Academic research sits at the center of this dementia and brain health question.

Multiple academic research labs are making genuine advances in Alzheimer’s drug development, with three new therapeutic pathways showing particular promise in 2025 and 2026. In February 2026, researchers at Indiana University School of Medicine identified the IDOL enzyme as a target that substantially reduces amyloid plaques in neurons, while Northwestern University scientists discovered that an inexpensive decades-old anti-seizure drug called levetiracetam can prevent toxic amyloid-beta from accumulating before plaques even form. Beyond these prevention and risk-reduction approaches, the FDA approved lecanemab and donanemab—the first disease-modifying treatments in over two decades that directly clear existing amyloid plaques from the brain. This article explores the current state of Alzheimer’s drug development across academic labs, the size of the pipeline, which candidates show the strongest evidence, and what realistic timelines patients and families should expect.

What New Drug Targets Are Academic Labs Discovering?
How Large Is the Current Drug Development Pipeline?
Which Drug Candidates Show the Strongest Evidence Currently?
How Are Academic Labs Using Advanced Technology to Accelerate Discovery?
What Barriers Still Prevent Faster Drug Development?
The Realistic Timeline for Combination Therapies
What This Progress Means for Patients and Caregivers
Conclusion

What New Drug Targets Are Academic Labs Discovering?

Academic research centers have shifted from studying amyloid plaques alone to examining the biological pathways that enable plaques to form and persist. Indiana University’s discovery of the IDOL enzyme represents this evolution: removing this enzyme from neurons in preclinical models substantially reduced amyloid buildup and may increase the brain’s overall resilience to disease. This finding is important because it suggests a different point of intervention than existing drugs—rather than clearing plaques that have already formed, IDOL-targeting compounds would prevent toxic accumulation in the first place. The Indiana team is currently developing compounds to target IDOL in preclinical models, meaning human trials are still years away.

Northwestern University’s parallel discovery about levetiracetam offers a different kind of advantage: it’s a drug that has been FDA-approved and used safely in epilepsy patients for decades, making it far faster to test in Alzheimer’s populations. The Northwestern study found that levetiracetam prevents the formation of toxic amyloid-beta oligomers—the smallest, most destructive forms of amyloid before they cluster into visible plaques. In contrast, the newly approved drugs lecanemab and donanemab work after plaques have already accumulated, which means they may be less effective in early disease stages when prevention is most valuable. Both approaches matter, but levetiracetam’s preventive mechanism addresses a different phase of disease development.

What New Drug Targets Are Academic Labs Discovering?

How Large Is the Current Drug Development Pipeline?

The scale of Alzheimer’s drug development has expanded substantially. Currently 138 drug candidates are being evaluated across 182 active clinical trials globally, according to pipeline analyses reviewed by pharmaceutical research sources. This is not a speculative future—these trials are actively enrolling patients right now. The National Institute on Aging (part of the National Institutes of Health) supports an even larger portfolio: 466 active clinical trials specifically focused on Alzheimer’s disease and related dementias, with diverse therapeutic targets ranging from amyloid-clearing approaches to tau protein modification to neuroinflammation.

However, the size of the pipeline does not mean rapid approvals are coming. Most drugs fail in clinical testing: they either don’t work as predicted or cause unacceptable side effects in humans. The path from preclinical discovery (like the IDOL work at Indiana University) to Phase 1 human safety trials typically takes 3-5 years. Phase 2 trials testing effectiveness take another 2-3 years, and Phase 3 trials with larger patient populations take an additional 2-3 years. Even with expedited regulatory pathways, a new drug discovered today would likely not reach patients for 7-10 years unless it advances through accelerated approval routes, which carry their own risks and require post-approval monitoring.

Which Drug Candidates Show the Strongest Evidence Currently?

Blarcamesine, developed by Anavex Life Sciences, recently completed Phase 2a and Phase 2b/3 trials with results presented at the AD/PD 2026 conference in March 2026. The data showed consistent correlation between brain volume preservation (a marker of slowed neurodegeneration) and treatment effect in early Alzheimer’s disease. This is notable because brain volume loss is a measurable biological endpoint, not just a cognitive score, giving it more credibility than self-reported symptom improvements. Blarcamesine targets the sigma-1 receptor, a neuronal protein involved in cell protection and communication, making it mechanistically distinct from the amyloid-focused drugs that preceded it.

Northwestern researchers also identified NU-9, an experimental drug that targets toxic amyloid-beta oligomers specifically. In mouse models with Alzheimer’s-like pathology, NU-9 dramatically reduced these toxic subtypes and prevented associated brain damage. The critical limitation here is that mouse models do not always translate to human efficacy—many drugs show promise in mice but fail in clinical trials because human brains are far more complex. NU-9 is still in preclinical development, meaning human trials have not yet begun. The POLARIS-AD trial testing AR1001 with over 1,500 patients is expected to report topline results in 2026, providing clearer evidence about whether recent therapeutic approaches work at scale in real patients.

Which Drug Candidates Show the Strongest Evidence Currently?

How Are Academic Labs Using Advanced Technology to Accelerate Discovery?

Artificial intelligence and machine learning are increasingly central to drug discovery for Alzheimer’s. The University of North Carolina’s Eshelman School of Pharmacy received a $6 million NIH award to advance AI-driven approaches to identifying and optimizing drug candidates. Traditional drug discovery relies on researchers screening compounds one by one in laboratory assays—a process that takes months or years to identify promising leads. AI-driven discovery can analyze thousands of molecular structures simultaneously, predicting which compounds are most likely to bind to target proteins, cross the blood-brain barrier (critical for brain drugs), and avoid toxicity.

However, AI acceleration does not eliminate the bottleneck of clinical testing. A computer model might identify a promising compound in weeks, but proving that compound actually helps Alzheimer’s patients still requires years of Phase 1, 2, and 3 trials. Additionally, AI models are trained on historical data, so they can miss entirely novel therapeutic mechanisms that don’t follow known patterns. The value of AI in Alzheimer’s research is real—it shortens the screening phase and reduces early development costs—but it cannot replace the fundamental requirement that new drugs must be rigorously tested in human populations before reaching patients.

What Barriers Still Prevent Faster Drug Development?

Clinical trial recruitment remains one of the largest obstacles. Alzheimer’s trials require patients in specific disease stages, and many trials exclude people with other health conditions or concurrent medications. Finding 1,500 eligible participants for the POLARIS-AD trial, while seemingly straightforward, actually took years of outreach and coordination across multiple medical centers. Additionally, trial participants must commit to frequent brain scans, cognitive testing, and visits—a burden that discourages participation, particularly from underrepresented populations who have historically had less access to research opportunities. Regulatory approval timelines, while critical for safety, also slow availability.

Even when Phase 3 data looks promising, the FDA review process takes 6 months to several years. Accelerated approval pathways can shorten this, but they require post-approval monitoring and may involve greater uncertainty. Another limitation specific to Alzheimer’s: measurable endpoints remain imperfect. Cognitive decline is the most clinically meaningful endpoint, but it’s subjective and variable. Biomarkers like amyloid levels and brain volume are more objective and detectable earlier, but their correlation with patient outcomes is still being established. This means that even when a drug reduces amyloid in a trial, proving it actually helps patients remember and function better is a separate, months-long process.

What Barriers Still Prevent Faster Drug Development?

The Realistic Timeline for Combination Therapies

Researchers at UCSF and other major institutions are projecting that within 5 to 10 years, combinations of existing and newly developed therapies will be capable of halting, reversing, or even preventing Alzheimer’s disease onset entirely. This projection is optimistic but grounded in current progress: if multiple single drugs are approved over the next 5 years, then testing safe combinations of those drugs would naturally follow. A combination targeting amyloid clearance (like lecanemab) plus amyloid prevention (like levetiracetam) plus tau stabilization (a separate mechanism still in development) could theoretically address multiple pathological processes simultaneously.

However, this 5-to-10-year window assumes continued funding, no major setbacks in ongoing trials, and successful FDA approval of drugs in early-stage development. Any significant failure—a large trial showing a leading candidate doesn’t work, or an unexpected safety signal—could delay the timeline by years. For families managing Alzheimer’s today, these future combinations are not imminent solutions, but they represent a realistic shift from the previous era when no disease-modifying options existed at all.

What This Progress Means for Patients and Caregivers

The expansion of the drug pipeline, from 0 disease-modifying therapies approved in 2020 to 2 now (lecanemab and donanemab), and from 0 novel preventive mechanisms in development to multiple (IDOL inhibitors, levetiracetam, sigma-1 receptor agonists), fundamentally changes the conversation around Alzheimer’s management. For the first time, conversations can center on disease modification rather than purely symptomatic management and cognitive support. Families should expect their physicians to increasingly discuss early detection, biomarker testing (amyloid PET scans, CSF tau levels), and eligibility for clinical trials or early-access drug programs.

Conclusion

Academic research labs are not advancing Alzheimer’s treatment incrementally—they are discovering fundamentally new mechanisms that attack the disease at different stages, from prevention to early detection to advanced symptomatic management. The Indiana IDOL discovery, Northwestern’s levetiracetam findings, and the NU-9 program represent genuine scientific progress, complemented by the FDA-approved drugs lecanemab and donanemab that have already entered clinical practice. With 138 drugs in active clinical trials and 466 NIA-funded trials underway, the pipeline is substantially larger than a decade ago, though most candidates will not successfully reach patients.

The realistic expectation is that patients diagnosed today may benefit from combination therapies within 5-10 years, and that future patients might receive preventive treatments before symptoms appear. In the near term, the most valuable action for individuals at risk is staying informed about clinical trial opportunities, undergoing early biomarker testing if cognitive concerns arise, and discussing emerging therapies with neurology specialists who track the latest approvals. This progress does not yet cure Alzheimer’s, but it moves the field from a disease with no disease-modifying options to one with multiple therapeutic pathways under active development.